Undisclosed VSTM-1 agonist
/ NextCure
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
January 18, 2024
NextCure Presents Preclinical Data on a Novel Therapeutic Candidate Targeting VSTM-1 for the Treatment of Progressive Inflammatory Airway Disorders
(GlobeNewswire)
- "NextCure...today announced the presentation of preclinical data relating to a novel humanized monoclonal antibody targeting VSTM-1, for the treatment of progressive inflammatory airway disorders, including chronic obstructive pulmonary disease (COPD)....The agonist antibody blocks neutrophil-mediated inflammation and cytokine production associated with tissue damage in vitro and ex vivo. Treatment with the agonist antibody reduces pulmonary pathology and prevents disease in animal models, including a highly relevant syngeneic mouse model engineered to express the human VSTM-1 protein."
Preclinical • Chronic Obstructive Pulmonary Disease
1 to 1
Of
1
Go to page
1